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Introduction
Melanoma, a cancer derived from pigment-producing melanocytes of the skin, is a disease of major
public health significance. Although it is the least common form of skin cancer, melanoma is by
far the most lethal due to its propensity to metastasize to a number of vital organs, including
the brain, lungs, liver, and other visceral organs (1). According to the American Cancer Society’s
2015 Cancer Facts & Figures statistics, melanoma accounts for <2% of all skin cancer cases but
is responsible for nearly 75% of skin cancer-related deaths, and it is predicted that melanoma will
cause 9,940 deaths in the U.S. this year (2). Worldwide estimates of mortality for melanoma are that
this disease is responsible for over 65,000 deaths annually (3). Moreover, recent data collected by
the Surveillance, Epidemiology, and End Results (SEER) Program show that melanoma incidence
rates have continued to increase over the previous 40 years (4). In the U.S. alone, the current annual
costs for treatment and productivity losses associated with melanoma are near $3.3 billion (5).
These numbers are even more staggering when considering a recent study by the International
Agency for Research on Cancer, which ranked North America only fourth in melanoma incidence
worldwide (6), thus highlighting the need to address melanoma as a global public health concern.
With these statistics in mind, it is vital that we increase our understanding of the progression of
melanoma so that we may improve current – and develop new – therapies for the treatment of this
cancer.
The B16 murine melanoma cell line is one of the most widely used models for studying the
progression and treatment of melanoma in pre-clinical settings (7, 8). Characterized by its rapid
outgrowth as both primary tumors and metastatic lesions, the B16-F1 subline has also been
shown to elicit dysfunctional CD8+ T cell responses (9) that mimic those frequently observed
in many melanoma patients (10–12), and soluble factors derived from this tumor have been
shown to alter the function of dendritic cells (DC) as well (13–15). We have recently described
a chemically mutated variant of B16 melanoma, D5.1G4, that is significantly less tumorigenic
and immunosuppressive than its wild-type counterpart (13, 15), though the basis for these differ-
ences between B16-F1 and D5.1G4 are poorly understood. Therefore, we sought to gain insights
into factors that regulate melanoma tumorigenicity by comparing whole genome expression pro-
files of these murine melanomas. The microarray dataset obtained from these experiments and
described herein offers a great resource for investigators wishing to study melanoma growth
and progression and will likely drive the design of future experiments aimed at understanding
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D5.1G4 murine melanoma cells were a generous gift of Dr.
Jerry Neiderkorn (University of Texas Southwestern Medical
School). B16-F1 murine melanoma cells were a generous gift of
Dr. Victor Engelhard (University of Virginia). These tumor cell
lines were grown in RPMI-1640 medium (Thermo Scientific,
Hudson, NH, USA) supplemented with 10% fetal bovine serum
(Premium Select, Atlanta Biologicals, Norcross, GA, USA), 2mM
L-glutamine, 2 grams/liter glucose, 2 grams/liter sodium bicar-
bonate, 100U/ml penicillin (American Type Culture Collection,
Manassas, VA, USA), and 100μg/ml streptomycin (ATCC). All
cells were grown at 37°C in 5% CO2 and were passaged at 80–90%
confluence.
Tumor Challenge
To evaluate tumor outgrowth, 4 105 B16-F1 or D5.1G4
melanoma cells in 0.2ml of endotoxin-free 1 PBS were injected
either subcutaneously in the nape of the neck or intravenously
via the lateral tail vein. Mice injected subcutaneously were moni-
tored every day for tumor formation. Following tumor formation,
tumor area was determined every 2–3 days using digital calipers
to take perpendicular diameter measurements of the tumor. Mice
were euthanized once tumor area reached >300mm2 or tumors
became necrotic. Mice challenged intravenously were euthanized
17 days post-tumor challenge, and lungswere harvested for count-
ing metastatic lesions under a dissecting microscope. Mice were
used between 8 and 12weeks of age, and all experiments were per-
formed in accordance with regulatory standards and guidelines
approved by the Hampden-Sydney College Animal Care and Use
Committee.
RNA Isolation
Prior to RNA isolation, tumor cells (1 106 cells/well) were
plated in 6-well tissue culture plates and incubated at 37°C in
5% CO2. After 24 h of culture, B16-F1 and D5.1G4 melanoma
cells were collected by cell scraping and centrifuged at 1,500 rpm
for 5min. Cell pellets were lysed with Buffer RLT containing β-
ME, and RNA was extracted using an RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s recommen-
dations. Following RNA extraction, samples were treated with
Amplification Grade DNase I (Life Technologies, Grand Island,
NY, USA) to digest any residual DNA, and RNA was quantified
using an Epoch Spectrophotometer (BioTek,Winooski, VT, USA).
A260/280 ratios for all samples were>2.0.
Whole Genome Expression Microarray
RNA samples (replicates of 3 for each melanoma cell line) were
diluted to 100 ng/μl, and ~5μg of RNA was shipped overnight
on dry ice to Arraystar, Inc. (Rockville, MD, USA) for anal-
ysis using the company’s gene expression service and Agilent
Mouse 4 44K Gene Expression Microarray v2 (Agilent Design
ID 026655). RNA integrity was assessed by standard denatur-
ing agarose gel electrophoresis. Sample labeling was performed
according to the Agilent One-Color Microarray-Based Gene
Expression Analysis protocol (Agilent Technology). Briefly, total
RNA from each sample was linearly amplified and labeled with
Cy3-UTP. The labeled cRNAs were purified using the RNeasy
Mini Kit (Qiagen). The concentration and specific activity of
the labeled cRNAs (pmol Cy3/μg cRNA) were measured using
a NanoDrop ND-1000. One microgram of each labeled cRNA
was fragmented by adding 11μl 10 blocking agent and 2.2μl
of 25 fragmentation buffer, then heated at 60°C for 30min,
and finally 55μl 2 GE hybridization buffer was added to
dilute the labeled cRNA. One hundred microliters of hybridiza-
tion solution were dispensed into the gasket slide and assem-
bled to the gene expression microarray slide [Agilent Mouse
4 44K Gene Expression Microarray v2 (Agilent Design ID
026655)]. The slides were incubated for 17 h at 65°C in an
Agilent hybridization oven. The hybridized arrays were washed
and fixed prior to scanning. Slides were scanned on the Agilent
DNA microarray scanner (G2505C) using the one-color scan
setting for 1 44K array slides (scan area= 61mm 21.6mm,
scan resolution= 5μm, dye channel set to Green, andGreen PMT
set to 100%).
Data Processing and Analysis
Agilent Feature Extraction software (version 11.0.1.1) was used
to analyze the acquired array images. Quantile normalization and
subsequent data processing were performed using theGeneSpring
GX v12.1 software (Agilent Technologies). After quantile nor-
malization of the raw data, genes for which at least three out
of six samples had flags in Detected (“All Targets Value”) were
chosen for further data analysis. Differentially expressed genes
with statistical significance were identified through Volcano Plot
filtering. D5.1G4 melanoma served as the reference sample, and
genes expressed at greater than or equal to twofold higher or
lower levels in B16-F1 (with a p value 0.05) were defined as
genes exhibiting differential expression between the two tumors
with statistical significance. Pathway analysis was performed
using the latest Kyoto Encyclopedia of Genes and Genomes
(KEGG) database and the standard enrichment computation
method.
Data Deposition
The data discussed in this publication have been deposited in
NCBI’s Gene ExpressionOmnibus (16) and are accessible through
GEO Series accession number GSE69908 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE69908). Data are freely avail-
able from this repository under file name GSE69908_RAW.tar,
which contains .txt files of the normalized signal intensities for
each Agilent Probe Name for all replicates of each sample.
Results
B16-F1 is a well-characterized murine melanoma cell line that
models the growth, metastasis, and disruption of anti-tumor
immunity often exhibited by aggressive melanomas in many
patients with this disease. D5.1G4 is a chemically mutated vari-
ant of B16 that is significantly less tumorigenic than its wild-
type counterpart, both with respect to its growth as primary
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tumors in the skin (Figure 1A) and with regard to its growth
as metastatic lesions in the lungs (Figure 1B). In order to
gain insight into factors that regulate melanoma growth and
progression, RNA was isolated from these two melanoma cell
lines for whole genome expression microarray analysis with the
Agilent Mouse 4 44K Gene Expression Microarray v2 (Agi-
lent Design ID 026655) that profiles the expression of 39,430
genes. Volcano Plot filtering was used to identify differentially
expressed genes exhibiting greater than or equal to twofold upreg-
ulation or downregulation in B16-F1 melanoma as compared
to D5.1G4 melanoma (Figure 1C). The dataset obtained from
this analysis, accessible through the NCBI GEO data reposi-
tory (16) at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE69908, revealed statistically significant upregulation of 1,462
genes and statistically significant downregulation of 1,935 genes
in B16-F1 melanoma. In order to better understand how these
FIGURE 1 |Whole genome microarray analysis of B16-F1 and D5.1G4
murine melanomas. C57Bl/6 mice were challenged with 4e5 B16-F1 or
D5.1G4 melanoma cells either subcutaneously (A) or intravenously
(B). Subcutaneous tumor outgrowth was monitored over time, and lung
metastatic lesions were enumerated 17days post-tumor challenge. Data
represent five mice per group and are graphed as the average with error bars
designating standard error of the mean. Data shown are representative of three
independent experiments. (C) RNA isolated from each respective melanoma cell
line was used for whole genome microarray expression analysis as described in
Materials and Methods. Volcano plot filtering was performed to identify genes
that were differentially expressed with statistical significance between the
B16-F1 and D5.1G4 melanomas. (D) KEGG pathway analysis was performed to
identify biological pathways significantly enriched with differentially upregulated
and downregulated genes in B16-F1.
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differences in gene expression might impact the biological prop-
erties of these melanoma cell lines, KEGG Pathway analysis was
performed to identify biological pathways in which there was a
significant enrichment of differentially expressed genes. In all, 71
KEGG pathways exhibited a statistically significant enrichment
(p< 0.05) in upregulated genes in B16-F1, and 15KEGGpathways
exhibited a statistically significant enrichment in downregulated
genes in this melanoma. The pathways with the 10 most signifi-
cant enrichments scores for both upregulated and downregulated
genes in B16-F1 are shown in Figure 1D, and the pathway-
associated genes exhibiting a greater than or equal to twofold
change in expression in this tumor versus the D5.1G4 melanoma
are listed in Table 1.
Discussion
The gene expression microarray data described herein and
available for further inspection and analysis at the publicly
accessible NCBI GEO repository are a valuable tool for inves-
tigators wishing to study the roles played by individual genes
and biological pathways in regulating melanoma tumorigenic-
ity. These data are likely to be useful for those wishing to
gain insights into melanoma-associated genes that influence var-
ious facets of tumor growth and progression, including cell
cycle regulation, survival, cell adhesion and motility, tissue inva-
sion and metastasis, and immune evasion. Our laboratory has
been particularly interested in this latter phenomenon, as CD8+
T cell responses to well-established B16 melanoma have been
shown to exhibit the type of dysfunction often associated with
anti-tumor T cell responses in melanoma patients (9–12). Of
note, our microarray data revealed a 16.77-fold upregulation
(p< 0.0001) of Tgfb1 gene expression in B16-F1 as compared
to its poorly tumorigenic D5.1G4 counterpart. It is therefore
possible that melanoma-derived TGFβ1 suppresses CD8+ T cell
effector function, leading to tumor immune escape and enhanced
outgrowth. We have also recently shown that B16-F1-derived
TABLE 1 | Differentially expressed genes associated with pathways with highest enrichment scores.
Pathway ID* (Mus musculus) Differentially expressed genes associated with indicated KEGG pathway
B16-F1 upregulated pathways
Melanogenesis Adcy7, Adcy9, Calm1, Creb3l1, Dvl2, Fzd2, Fzd6, Fzd7, Fzd9, Kit, Map2k1, Mapk1, Mc1r, Nras, Tcf7, Tcf7l1, Tyr,
Wnt3a, Wnt9b
Rap1 signaling pathway Adcy7, Adcy9, Adora2b, Akt2, Angpt2, Arap2, Calm1, Efna1, Efna4, Fgfr1, Itgb1, Kit, Lpar2, Map2k1, Mapk1,
Mapk11, Nras, P2ry1, Pard6a, Pfn4, Pik3cd, Plcg1, Rac1, Rapgef3, Rasgrp2, Rasgrp3, Rgs14, Rhoa, Sipa1l1, Thbs1
Proteoglycans in cancer Akt2, Col1a1, Ctsl, Ddx5, Eif4b, Fgfr1, Fzd2, Fzd6, Fzd7, Fzd9, Grb2, Hpse, Itgav, Itgb1, Kit, Lpar2, Map2k1, Mapk1,
Mapk11, Nras, Nudt16l1, Pik3cd, Plcg1, Plcg2, Rac1, Rhoa, Tgfb1, Thbs1, Tlr2, Wnt3a, Wnt9b
Pathways in cancer Akt2, Axin1, Cdk2, Col4a1, Col4a4, Dvl2, Egln1, Epas1, Fgfr1, Fos, Fzd2, Fzd6, Fzd7, Fzd9, Grb2, Itgav, Itgb1, Kit,
Lama5, Lamb1, Map2k1, Mapk1, Msh3, Nras, Pik3cd, Plcg1, Plcg2, Pten, Rac1, Rhoa, Rxrg, Tcf7, Tcf7l1, Tgfb1,
Traf4, Wnt3a, Wnt9b, Xiap
PI3K–Akt signaling pathway Akt2, Angpt2, Atf2, Cdk2, Col1a1, Col4a1, Col4a4, Creb3l1, Efna1, Efna4, Eif4b, Fgfr1, Gnb4, Grb2, Itga1, Itga7,
Itgav, Itgb1, Kit, Lama5, Lamb1, Lpar2, Map2k1, Mapk1, Nr4a1, Nras, Pck2, Pik3cd, Ppp2r1a, Ppp2r2b, Ppp2r3d,
Prakaa1, Pten, Rac1, Thbs1, Them4, Tlr2, Ywhaz
N-glycan biosynthesis Alg14, Alg5, Alg8, B4galt2, B4galt3, Fut8, Man1c1, Man2a1, Rft1, St6gal1, Stt3a
Estrogen signaling pathway Adcy7, Adcy9, Akt2, Atf2, Calm1, Creb3l1, Fos, Grb2, Hspa8, Itpr3, Map2k1, Mapk1, Nras, Pik3cd, Prkcd, Shc4
Inositol phosphate metabolism Aldh6a1, Inpp5b, Ippk, Isyna1, Minpp1, Pi4k2b, Pik3cd, Pikfyve, Pip4k2b, Plcg1, Plcg2, Pten
Colorectal cancer Akt2, Axin1, Fos, Map2k1, Mapk1, Msh3, Pik3cd, Rac1, Rhoa, Tcf7, Tcf7l1, Tgfb1
VEGF signaling pathway Akt2, Map2k1, Mapk1, Mapk11, Nras, Pik3cd, Plcg1, Plcg2, Ppp3cc, Rac1, Sphk1
B16-F1 downregulated pathways
Axon guidance Ablim1, Dcc, Epha1, Epha2, Epha3, Epha4, Epha7, Ephb6, Gnai1, Plxna4, Plxnb3, Ptk2, Rgs3, Robo1, Sema3c,
Sema3f, Sema4d, Sema4f, Sema6a, Sema6c, Slit2, Srgap1
Protein digestion and absorption Coll11a2, Col17a1, Col18a1, Col1a2, Col2a1, Col4a2, Col4a4, Col9a1, Mme, Prcp, Slc7a9, Try4, Try5
Alanine, aspartate, and glutamate metabolism Abat, Ass1, Ddo, Gfpt1, Gfpt2, Gls, Glul, Il4i1
Proteoglycans in cancer Ank3, Araf, Camk2b, Camk2d, Cav2, Cd44, Col1a2, Fas, Fgf21, Fgf9, Fn1, Fzd8, Gpc1, Hbegf, Hspg2, Igf1r, Mapk13,
Mras, Mtor, Ppp1r12a, Ptk2, Sdc4, Slc9a1, Wnt10a, Wnt5b, Wnt6
SNARE interactions in vesicular transport Stx11, Stx16, Stx17, Stx3, Vamp1, Vamp5
NOD-like receptor signaling Ccl2, Ccl5, Map3k7, Mapk13, Naip7, Nlrp1a, Nod1, Tnfaip3
Cocaine addiction Cdk5r1, Creb3, Gnai1, Gnas, Grm2, Maoa, Slc18a1
ECM-receptor interaction Cd44, Col11a2, Col1a2, Col2a1, Col4a2, Col4a4, Fn1, Gp9, Hspg2, Sdc4
Gap junction Gja1, Gnai1, Gnas, Gucy1a3, Gucy1b2, Pdgfrb, Plcb4, Tuba1a, Tubb2b, Tubb3
Wnt signaling pathway Apc, Camk2b, Camk2d, Fzd8, Map3k7, Nfatc1, Nkd1, Nkd2, Plcb4, Porcn, Vangl1, Wnt10a, Wnt5b, Wnt6
*Pathways with the 10 highest enrichment scores for differentially upregulated and downregulated genes in B16-F1 as compared to D5.1G4. Genes listed are those within the indicated
pathways that exhibit a greater than or equal to twofold change in expression in B16-F1 with a p value <0.05.
Frontiers in Immunology | www.frontiersin.org September 2015 | Volume 6 | Article 4524
Hargadon Melanoma gene expression analysis
TGFβ1 alters that maturation and activation of tissue-resident
DC and promotes their acquisition of a phenotype that is likely
to favor tumor progression (15). Tumor-associated glycans have
also been reported to promote immunosuppressive activity in
DC (17), and KEGG pathways relating to glycan biosynthesis
and cancer-associated proteoglycans were enriched with several
genes exhibiting significant upregulation in B16-F1 (Table 1). It
is interesting to speculate that overactivation of these and related
immunoregulatory genes in B16-F1 may suppress cytotoxic T cell
function or preclude efficient stimulation of CD8+ T cells by
tumor-associated DC, thereby promoting tumor immune escape
and enhanced outgrowth.
In addition to the role that overexpressed genes might play in
promoting immune escape by B16-F1 melanoma, it is likely that
downregulation of certain genes by B16-F1 may also contribute
to escape from anti-tumor immune responses, even those that
are robustly activated and exhibit significant effector function.
For instance, our microarray data revealed significant down-
regulation of Cd72 (9.93-fold, p< 0.001) and Fas (9.91-fold,
p< 0.01) gene expression in B16-F1 melanoma. CD72 functions
as a cell adhesion and costimulatory ligand for the CD5 recep-
tor on T cells (18), and its downregulation may limit high-
affinity interactions between melanoma cells and tumor antigen-
specific T cells. Likewise, melanoma-associated downregulation
of Fas may promote tumor escape from activated tumor-specific
T cells expressing FasL. Such findings might explain B16-F1
melanoma outgrowth in the face of the functional anti-tumor
CD8+ T cell responses that are elicited against this tumor in
early stages of its growth (9), and subsequent tumor progres-
sion could then be compounded by the overexpression of genes
with active immunosuppressive functions as described above.
It is also interesting that there is a significant enrichment of
downregulated genes associated with the NOD-like receptor
signaling pathway in B16-F1 melanoma. Downregulation of the
Ccl2 and Ccl5 genes associated with this pathway may preclude
efficient recruitment of various immune effectors into tumors
or tumor-bearing tissue. Downregulation of other genes associ-
ated with this pathway, such as the Nod1 gene that promotes
inflammation and Nlrp1 gene that functions to induce apop-
tosis, would also be expected to contribute to immune escape,
enhanced survival, and the overall protumorigenic nature of this
melanoma.
In conclusion, this comparative analysis of the whole genome
expression profiles for the highly tumorigenic B16-F1 and poorly
tumorigenic D5.1G4 melanomas offers a resource of data that
provides significant insights into factors that regulate melanoma
tumorigenicity. Those genes and pathways highlighted in this
report are just a sample of the many that are likely to be of interest
to tumor immunologists and cancer biologists, and it is hoped that
the data obtained from this study will drive future investigation
into the dysregulation of individual genes and biological pathways
in melanoma that will enhance our understanding of this tumor’s
progression and inform the design of new and improved therapies
for the treatment of this cancer.
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